NCT03318640

Mindfulness and Cognition in Schizophrenia

Terminated NA Last updated 18 December 2023

What this trial tests

NA trial testing Mindfulness in Schizophrenia in 34 participants. Terminated before completion.

Timeline

11 September 2018

Primary endpoint
3 May 2021

12 July 2021

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Saint Etienne
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	34
Start date	11 September 2018
Primary completion	3 May 2021
Estimated completion	12 July 2021
Sites	1 location across France

Drugs / interventions tested

• Mindfulness

Conditions studied

• Schizophrenia — all drugs for Schizophrenia →

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Who can join

Adults 18 to 55, male only, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mindfulness (innovative and integrative practice in care) allows the individual to adapt his/her behavior (physical and emotional), in a stressful environment, by regulating cardiac activity, especially the parasympathetic system. In schizophrenia, despite the positive effect of treatments on symptoms (delusions and hallucinations), patients have altered markers of the parasympathetic (high frequency, HF) system. The investigator propose a session of Mindfulness Based Stress Reduction (MBSR) for patients suffering from schizophrenia in order to measure the impact on the parasympathetic system (HF), self-awareness (being well in one's body and being aware of their own actions; EASE) and cognition (attention) in relation to the management of conflicts or emotions. The study compare with patients who receive a session of techniques based on the management of emotions and social cognition (cinemotion, Michael's Game and Tom Remed).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.